Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
Recruiting · NCT04598009 · Registry updated 2026-08-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 2 | 2026-08-18 | NCT04598009 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Array BioPharma | 3 |
| University of California, San Francisco | 637 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UC San Diego Moores Cancer Center | La Jolla | United States | 199 |
| University of California, San Francisco | San Francisco | United States | 294 |